4CPS-249 Eltrombopag for treatment of autoimmune thrombocytopenia associated with COVID-19 vaccine: a case report

4CPS-249 Eltrombopag for treatment of autoimmune thrombocytopenia associated with COVID-19 vaccine: a case report

Background and importanceCases of thrombocytopenia, including immune thrombocytopenia (ITP), have been reported after receiving Vaxzevria, typically within the first 4 weeks after vaccination.Very rarely, these events presented with very low platelet levels (

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of hospital pharmacy. Science and practice 2022-03, Vol.29 (Suppl 1), p.A111-A111
Hauptverfasser: Zurita, B, Campos-Baeta, Y, Estelrich, M, Sanchez, E, Martí-Navarro, M
Format: Artikel
Sprache:eng
Schlagworte:
Case reports
Conflicts of interest
Coronaviruses
COVID-19 vaccines
Section 4: Clinical pharmacy services
Thrombocytopenia
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background and importanceCases of thrombocytopenia, including immune thrombocytopenia (ITP), have been reported after receiving Vaxzevria, typically within the first 4 weeks after vaccination.Very rarely, these events presented with very low platelet levels (
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2022-eahp.232